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Abstract 
PURPOSE: The purpose of this study is to examine whether inpatients with liver disease at 
University of Kentucky Hospital receiving lactulose are meeting the protocol of 2-4 bowel 
movements per day. Research shows that lactulose is the medication of choice used to treat and 
prevent hepatic encephalopathy (HE). Additional lactulose interventions, a patient’s MELD 
score, and GCS score will be examined in this study as well. This information would be 
beneficial to providers and nurses because it would provide data on patients who might require 
more lactulose interventions than others.  
METHODS: Retrospective chart reviews of 70 inpatients with liver disease receiving lactulose at 
the University of Kentucky from January 1, 2017 to December 31, 2017 were performed. 
Number of daily movements, MELD score, GCS score, PRN lactulose administration, lactulose 
enema administration, and narcotic administration were examined during the first five days of 
hospitalization.  
RESULTS: In the sample, a higher percentage of patients (>50%) did not meet the protocol of 2-
4 daily bowel movements during the first five days of hospitalization. There was no association  
shown for patients who had a higher MELD score ≥ 25 on whether or not they met the goal of 2-
4 bowel movements per day or received additional lactulose interventions. Those who had a 
GCS of ≤ 14.5 were more likely to receive lactulose enemas on day 1 and 2 (p=0.0021, 0.0063) 
and no significance was shown for the remaining days or PRN lactulose. Narcotic administration 
did not affect this group, as there was no association shown between GCS and narcotic 
administration.  
CONCLUSIONS: More than 50% of patients were not meeting the goal of 2-4 daily bowel 
movements during the first five days of hospitalization. Those who are confused seem to require 
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additional lactulose during the early initial days of hospitalization. This information can help 
nurses and physicians better understand lactulose titration and administration in the hospital 
setting.  
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Does a Nonstandardized Lactulose Administration Practice affect Hepatic Encephalopathy in 
Patients with Liver Disease in the Acute Care Setting? 
Introduction 
Liver disease is prevalent in the United States. In 2015, the number of adults diagnosed 
with liver disease was 3.9 million (Centers for Disease Control and Prevention [CDC], 2017). In 
2014, there were 38,170 deaths from liver disease (CDC, 2017). In the state of Kentucky, liver 
disease falls in the top fifteen causes of death for patients aged 45 to 75 (Kentucky Life 
Expectancy, 2017).  
According to the American Liver Foundation (2017), over 17,000 Americans are on the 
waiting list for a liver transplant. A patient’s Model for End-Stage Liver Disease (MELD) score 
helps prioritize patients who are waiting for a liver transplant. The MELD score is numeric scale 
that ranges from 6 (less ill) to 40 (severely ill) and the score determines how urgent the liver 
transplant is needed within the next three months (Sutter Health, 2014). The Liver Specialists of 
Texas (2011) stated that the higher the MELD score, the more ill the patient is. Most transplant 
programs are performing liver transplants with a MELD score of >25. The components utilized 
to measure a MELD score include whether or not a patient has had dialysis twice in the past 
week and the specific lab values: creatinine (Cr), total bilirubin, sodium (Na), and the 
international normalized ratio (INR), (MD Calc, 2016). The MELD score has been validated 
since 2001 and applied to numerous clinical situations (Tsang & Admed, 2013). Since its 
implementation, use of it has led to a sharp reduction in waiting list registrations and reduced 
mortality on the liver transplant waiting list without affecting post-transplant outcomes (Tsang & 
Admed, 2013).  
LACTULOSE ADMINISTRATION	 	 4	
	
Patients with liver disease are at risk for developing hepatic encephalopathy (HE), which 
causes changes in an individual’s mental status that can range from mild confusion to a comatose 
state. Numerous factors contribute to the pathophysiology of HE, which plays a role in altering 
the function of neuronal cells. The common agents that are thought to cause HE include 
inflammatory cytokines, benzodiazepine-like compounds (i.e. gamma-amino butyric acid), 
manganese deposition in the basal ganglia, and ammonia—the most studied agent. Ammonia, a 
gut-derived nitrogenous toxin, is produced by bacterial metabolism of urea from proteins 
ingested from an individual’s diet. The liver metabolizes ammonia and it is cleared by the 
kidneys. When patients have liver damage, the metabolism of ammonia is impaired. Portal 
hypertension causes shunting of ammonia rich blood to the systemic circulation without 
detoxification. Ammonia crosses the blood brain-barrier and is metabolized in the astrocytes by 
glutamine synthetase. As a result, ammonia and glutamate are converted to glutamine. The 
increase of glutamine in the brain causes an osmotic gradient that produces astrocyte swelling 
and generation of reactive oxygen species, which plays role in the cerebral dysfunction 
associated with HE. (Elwir & Rahimi, 2017) 
Diagnosis of HE can be challenging and tends to be a clinical diagnosis (Elwir & Rahimi, 
2017). There are numerous tools that can be used to help diagnose HE including the West Haven 
Criteria, the International Society for Hepatic Encephalopathy and Nitrogen Metabolism 
(ISHEN), Full Outline of Unresponsiveness (FOUR), the Glascow Coma Scale (GCS), Hepatic 
Encephalopathy Scoring Algorithm (HESA), Clinical Hepatic Encephalopathy Staging Scale 
(CHESS), and the Spectrum of Neurocognitive Impairment in Cirrhosis (SONIC). The West 
Haven Criteria is the most popular tool used for diagnosing HE. However, the GSC can be used 
for individuals with severe encephalopathy. When diagnosing HE, a provider must rule out other 
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causes such as medications, electrolyte disorders, infection, withdrawal, hypoglycemia, or 
hypercapnia. (Hepatitis C Online)  
HE treatment targets the gut bacteria due to the hyperammonia state in the body. 
Lactulose, a nonabsorbable disaccharide, is used to prevent and treat HE. This drug is 
metabolized by the colonic microbiota and forms short chains organic acids. The creation of an 
acidic environment helps prevent the growth of ammonia producing bacteria and support the 
growth of favorable microorganisms. In an acidic environment, ammonia converts to 
ammonium, which is not absorbed and lowers the ammonia load. Lastly, the laxative effects of 
lactulose help remove nitrogen-containing substances from the gastrointestinal tract. Lactulose 
can be administered orally or rectally and needs to be titrated to a goal of 2-4 bowel 
movements/day. (Elwir & Rahimi, 2017) 
  Lactulose is the drug of choice for preventing and treating HE. Research shows that 
lactulose administration needs to be titrated for the patient to have 2-4 bowel movements a day. 
In the hospital setting, some patients may not meet the goal of 2-4 bowel movements a day, 
increasing their risk of becoming encephalopathic. Often times, an additional dose of lactulose or 
a lactulose enema is ordered to promote a bowel movement. The purpose of this study is to 
perform a retrospective chart review to examine whether or not inpatients with liver disease at 
University of Kentucky Hospital receiving lactulose for liver disease etiologies are meeting the 
protocol of 2-4 bowel movements per day. Additional lactulose interventions and a patient’s 
MELD score and GCS score will be also be examined in this study. If these patients are not 
meeting the protocol of 2-4 bowel movements per day, a standardized order set could be 
beneficial in this patient population that would help improve nurse-provider communication 
about titrating bowel movements to lactulose administration.  
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This study is important because it will provide information regarding whether or not 
patients with liver disease receiving lactulose are meeting the protocol of 2-4 bowel movements 
per day in the hospital setting. Examining an individual’s MELD score could show that a higher 
MELD score may require additional lactulose interventions. Examining an individual’s GCS 
could show that a score ≤ 14.5 may require additional lactulose interventions. Providers at UK 
hospital do not document the West Haven Criteria for diagnosing HE. Consequently, GCS will 
be the variable used for assessing level of conscious (LOC) in this population because it is 
assessed at least two times a day by the nursing staff at UK. This information would be 
beneficial to providers because it would provide patients at risk for developing HE and those 
who need more lactulose interventions than others.   
Background 
Lactulose is the primary drug used for preventing and treating HE in patients with liver 
disease. HE occurs when ammonia levels rise due to diffuse brain edema and structural brain 
injury resulting in neuronal dysfunction (Wijdicks, 2016). The rise of ammonia levels causes 
mental status, behavioral, and motor changes (AACN, n.d.). Consequently, drug therapies to 
prevent and treat HE are aimed toward lowering ammonia levels (Wijdicks, 2016). Lactulose 
works by removing the nitrogen containing substances from the gastrointestinal tract and can be 
given orally or rectally to achieve 2-4 bowel movements daily (Elwir & Rahimi, 2017). As a 
result, ammonia is eliminated from the body through bowel movements. If an individual does not 
have 2-4 bowel movements per day, ammonia levels can accumulate in the body and cause 
mental status changes. The National Organization for Rare Disorders (2011) states that the exact 
incidence of HE is unknown but it is most often associated with cirrhosis. The organization 
found that 70% of individuals with cirrhosis develop symptoms of HE. In 2003, HE related 
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hospitalizations cost over 930 million dollars (The Hepatology Center for Educational Expertise, 
2012). Morgan, Jenkins-Johns, Radwan, Conway, and Currie (2014) found that HE increased the 
mortality risk in patients with liver disease. The study found that in 551 patients with HE, 304 
(55.2%) died during the follow up period.  
Research indicates that lactulose is the gold standard of treatment for HE. A study by 
Sharma, Sharma, Agrawal, and Sarin (2009) found that 19.6% of patients who were administered 
lactulose suffered from HE while 46.8% of patients in the placebo group suffered from HE. 
Sharma, Sharma, Agrawal, and Sarin (2012) showed that 6 (11%) out of 55 patients who 
received lactulose developed HE while 14 (28%) out of 50 patients who did not receive lactulose 
developed HE. This study also proved that lactulose improved minimal hepatic encephalopathy 
(MHE) in 66% of patients who were given lactulose. Lactulose administration significantly 
lowered abnormal neuropsychological tests, reduced the risk of no improvement, and decreased 
the time to complete a number connection test when compared to a placebo or no intervention 
(Luo, Li, Lu, & Cao, 2011). Similarly, Prasad et al. (2007) showed that the mean number of 
neuropsychological tests decreased after a 3-month course of lactulose administration compared 
to no lactulose treatment for 3 months. The mean number of abnormal psychometric tests 
decreased significantly when patients were given lactulose compared to no lactulose 
administration (Dhimen et al., 2000). The evidence shows that lactulose prevents HE from 
occurring in patients with liver disease. Therefore, it is essential that all inpatients taking 
lactulose are meeting the goal of 2-4 bowel movements per day.  
When research was done about the role of lactulose and other drugs, most showed that 
lactulose is the drug of choice of treatment for HE. Mittal, Sharma, Sharma, and Sarin (2011) 
studied the effects of lactulose, probiotics, l-ornithine l-aspartate (LOLA) and no treatment on 
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HE. They found that lactulose had the strongest results among the three interventions through 
significance in neuropsychological test improvement, decreased blood ammonia levels, and the 
SIP questionnaire (this tool assesses the effect of HE on daily functioning). Lactulose, either 
alone or in combination with Rifaximin, is the treatment of choice for HE (Zhan & Stremmel, 
2012). Tapper, Jiang, and Patwardhan (2015) examined the effects of existing and evolving 
therapeutic treatment for HE and found that lactulose is the first line of therapy for HE compared 
to other medications.  
According to Kamath & Kim (2007), A patient’s MELD score can be used to predict survival 
in patients with different levels of liver disease and their severity. MELD scores were initially 
calculated to predict the patient survival rates following the placement of transjugular 
intrahepatic portosystemic shunts (TIPS). However, the MELD score has become an acceptable 
way to predict long-term survival in patients with cirrhosis, variceal bleeding, Hepatitis C-
cirrhosis, alcoholic hepatitis, fulminant hepatic failure, other chronic liver diseases, and hepatic 
cellular carcinoma. MELD scores are also used for liver transplant purposes. According to the 
United Network for Organ Sharing, the higher the MELD score, the more urgently a patient 
needs a liver transplant. Patients with a higher MELD score will always be considered first 
before those who have a lower MELD score, regardless of how long they have been on the 
waiting list.  
The GCS has been in healthcare since the 1980s. According to Nickson (2017), this scale is 
the most widely recognized of all conscious level scoring systems in the world. The scale 
measures the mental status of patients according to three categories: verbal response, motor 
response, and eye response. For eye response, the patient is scored based on (1) no eye opening, 
(2) eye opening to pain, (3) eye opening to verbal command, and (4) eyes opening 
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spontaneously. For verbal response, the patient is scored based on (1) no verbal response, (2) 
incomprehensible sounds, (3) inappropriate words, (4) confused, and (5) oriented. For motor 
response, the patient is scored based on (1) no motor response, (2) abnormal extension to pain, 
(3) abnormal flexion to pain, (4) withdrawal from pain, (5) localizing pain, and (6) obeys 
commands. The GCS can range from 3-15 and the total of these scores add up to 15, which 
indicates the patient is alert and oriented. Using GCS has been accepted as a mental status 
assessment method in the hospital setting. For this study, GCS scores are used for the mental 
status assessment in patients receiving lactulose. (Jain & Iverson, 2018)  
Lactulose is given to inpatients at University of Kentucky of hospital that have liver disease 
and it is important that they are meeting the protocol of 2-4 bowel movements per day to prevent 
changes in mental status from occurring. If a patient becomes encephalopathic, additional 
interventions are needed such as an additional dose of lactulose or a lactulose enema. This results 
in increased costs and length of stay for patients. There is an economic burden associated with 
HE. From 2005-2009, the total costs of hospitalizations increased by 55.1%. The average length 
of stay increased from 8.1 days in 2005 to 8.5 days in 2009 for patients with HE. Patients who 
had HE during hospitalization, had increased costs due to increased resource utilization, 
increased number of inpatient procedures, and an increased average length of stay. The total 
costs went from $4.68 billion in 2005 to $7.25 billion in 2009 for patients who suffered from HE 
while hospitalized. (Flamm, 2018)  
The conceptual framework guiding this study is the Logic Model. The purpose of the study is 
to examine the number of bowel movements patients with liver disease who are receiving 
lactulose are having each day and assess whether or not additional lactulose interventions are 
required. The context of this study is to examine the Internal Medicine inpatient cohort at UK 
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hospital. The inputs will be Sunrise Clinical Manager, which is the charting system at UK 
hospital, to collect the raw data which will then be entered and stored on REDCap. The activities 
will be statistical analysis on SPSS version 25 of data to see if the protocol of 2-4 daily bowel 
movements is being met. The outputs will be the results of the study, specifically the percentage 
of patients who are meeting the protocol of 2-4 daily bowel movements and whether or not they 
required additional lactulose interventions. The effects of this study will be what the author does 
with the results and what further studies can be performed to help meet this protocol in the 
inpatient setting. (Community Tool Box, 2018) 
Purpose 
The literature shows that Lactulose is the drug of choice for prevention and treatment of HE 
in patients with liver disease. The purpose of this study was to examine whether inpatients with 
liver disease at University of Kentucky Hospital receiving lactulose are meeting the protocol of 
2-4 bowel movements per day. Additional interventions (administration of PRN doses of 
lactulose or lactulose enemas) and a patient’s MELD score and GCS score will be examined in 
this study as well.  
The specific objectives are:  
OBJECTIVE 1: To determine the proportion of patients with liver disease receiving 
lactulose at UK hospital are meeting the protocol of 2-4 bowel movements per day, and 
examine the demographic differences among the sample population in the study.  
OBJECTIVE 2: To assess if inpatients with liver disease receiving lactulose at UK 
hospital with a MELD score ≥ 25 are meeting the goal of 2-4 bowel movements per day 
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during the first five days of hospitalization and how often they are requiring additional 
lactulose interventions.  
OBJECTIVE 3: To assess if inpatients with liver disease receiving lactulose at UK 
hospital with a GCS ≤14.5 are meeting the goal of 2-4 bowel movements per day during 
the first five days of hospitalization, how often they are requiring additional lactulose 
interventions, and whether or not they received narcotics.  
Methods 
A retrospective chart review was conducted including patients that were admitted to 
University of Kentucky Hospital with a history of or diagnosis of HE on the Internal Medicine 
service line. Data was collected through a sample from January 1, 2017 to December 31, 2017 of 
75 randomly selected charts from the electronic medical records (EMR) gathered by the CCTS 
from the KMSF database. The principle investigator (PI) collected data from the EMR and 
entered and stored them on REDCap’s protected server. MRNs were entered on REDCap, but 
not exported into SPSS for the data analysis. Once the data was collected and entered into the 
data collection tool, the de-identified data was uploaded into SPSS version 25 statistical software 
for data analysis with statistical significance to be a p-value of <0.05. 
Setting 
The study took place at University of Kentucky (UK) hospital in Lexington, Kentucky. UK 
hospital is committed to the pillars of academic health care—research, education, and clinical 
care (UK Healthcare). The hospital is dedicated to the health of Kentucky to provide the most 
advanced patient care and serve as an information resource (UK Healthcare). The 9th and 10th 
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floors in Pavilion A and the 5th floor and two wings on the 6th floor in Pavilion H make up the 
Internal Medicine cohort at UK hospital with 122 beds.  
Sample  
Patient inclusion criteria were: 1) patients aged at least 18 years old; 2) patients with history 
of or diagnosis of HE; 3) Length of stay ≥ 5 days.  Patient exclusion criteria were: 1) patients 
aged less than 18 years; 2) patients receiving lactulose for non-liver disease etiologies (i.e. 
constipation); 3) Length of stay ≤ 5 days. Demographic variables will be extracted for each 
individual in the study including age, sex, race, and admitting diagnosis. We reviewed all 
patients’ charts that were identified with a history or diagnosis of hepatic encephalopathy from 
January 1, 2017 to December 31, 2017. Seventy-five charts were reviewed.  We excluded 5 
patients as not meeting criteria leaving 70 patients who met the inclusion and exclusion criteria. 
Data Collection 
Approvals from the University of Kentucky Institutional Review Board (IRB) and the 
University of Kentucky Nurse Research Board were obtained prior to the collection of data. This 
study was based on a retrospective chart review. Patient charts were collected from the KSMF 
electronic patient database. Seventy-five randomly selected charts were identified using the 
ICD10 CM coding scheme with diagnosis or history of hepatic encephalopathy ICD-10 code 
K72.90. During data collection, patient records were accessed using the patient medical record 
number (MRN), data was abstracted based on listed variables in Table 1, and data was entered 
stored on REDCap, a protected data collection server. Please refer to Table 1 for a list of 
variables that were reviewed, which included demographic variables (length of stay, age, race, 
sex, admitting diagnosis), the number of daily bowel movements in 24 hours for the first give 
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days of hospitalization, daily PRN oral lactulose administration, daily lactulose enema 
administration, admit MELD score, average daily GCS score, and daily narcotic administration. 
Specific laboratory values were collected on day one of hospitalization to calculate the admit 
MELD score: INR, Cr, Na, total bilirubin, and whether or not the patient received dialysis twice 
in the past week. The MELD score was then calculated by using the MD Calc website. Please 
see table 2 for the list of narcotics patients received in this study.  
Data Analysis 
 Descriptive statistics, including frequency distributions, means, percentages  and standard 
deviations (SD) were used to describe patients’ demographic measures and whether or not the 
protocol of 2-4 bowel movements were met. The chi-square test of association was used to test 
for associations between categorical variables. The categorical variables in the study were: 
patients with a MELD score ³ 25 and whether or not they met the criteria of 2-4 daily bowel 
movements (yes/no), and whether or not they received additional lactulose interventions (yes/no 
for lactulose enema or PRN lactulose administration) and patients with an GCS £ 14.5 and 
whether or not they met the criteria of 2-4 daily bowel movements (yes/no), and whether or not 
they received additional lactulose interventions (yes/no for lactulose enema or PRN lactulose 
administration) and whether or not narcotics were administered (yes or no). All analysis was 
conducted using SPSS version 25; an [alpha] level of .05 was used for statistical significance in 
all analysis 
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Results 
Sample Characteristics  
 A total of 70 patients who met the inclusion/exclusion criteria were included in this 
study. Five patients did not meet the criteria because lactulose was not ordered for them until 
after five days of hospitalization. The average age of patients was 57.6 (SD=10.7; see Table 3), 
with the majority of the patients being White (95.7%) and male (51.4%). The median length of 
stay (LOS) was 11.5 days with a range of 6-20. The majority of patients had an admitting 
diagnosis of non-liver disease etiology (62.9%).  
Bowel Movements 
 Patients were defined as meeting the criteria each day if the number of daily bowel 
movements was recorded as 2-4. Of the five days, the highest percentage of patients not meeting 
the criteria was day 1 (77.36%; see Table 4). Greater than 50% of patients did not meet the 
criteria on the four additional days.  
MELD Score  
 Patients who presented with a MELD score ≥ 25 on the first day of admission were 
analyzed specifically. There was no association between a higher MELD score and whether or 
not the criteria of 2-4 bowel movements were met (see Table 5). Also, there was no association 
among a higher MELD score and requiring additional lactulose interventions (PRN lactulose or 
lactulose enema).  
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GCS Score 
 Patients who had an average daily GCS score of ≤ 14.5 were analyzed specifically. On 
day 1 and day 2 of hospitalization, significance was shown for lactulose enema administration 
(p=0.0021, 0.0063 respectively, see Table 6). There was no association between a confused 
patient and whether or not the criteria of 2-4 bowel movements were met. Also, there was no 
association among a confused patient and requiring PRN lactulose or lactulose enemas on days 
3, 4, and 5. There was no association between confusion and narcotic administration.  
Discussion 
  This study aimed to better understand lactulose administration for patients with liver 
disease in the hospital setting. Additional lactulose interventions were examined to see if those 
with a higher MELD score or confusion required more lactulose. Understanding the findings in 
this study will help nurses and physicians understand the importance of lactulose titration in the 
hospital setting.  
 Research has shown that a goal of 2-4 bowel movements per day helps prevent and treat 
HE. This study has shown that over half of the patients are not meeting the criteria of 2-4 daily 
bowel movements during the first five days of hospitalization. Therefore, nurses may not be 
titrating lactulose administration to bowel movements properly.  As a result, patients are at an 
increased for becoming encephalopathic because they are not clearing the ammonia through the 
stool. Physicians may not be aware that they their patients have not the met the goal of 2-4 bowel 
movements until the following day because the nurse did not inform them the prior day. 
Therefore, better methods of communication need to be established among the nurses and 
physicians about the number of bowel movements their patients are having.  
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 When examining a patient’s MELD score, the severity of a patient’s liver disease did not 
seem to impact whether or not they were meeting the criteria of 2-4 bowel movements daily. 
This patient population did not require additional lactulose interventions. This indicates that 
although a patient may have a higher MELD score, lactulose titration does not need to be done 
any differently.  
 When examining a patient’s GCS score, there was no significance shown for whether or 
not they are meeting the criteria of 2-4 bowel movements per day. However, on day one and day 
two of hospitalization, this population was requiring the additional intervention of lactulose 
enemas. This indicates that upon admission, confused patients may need more lactulose 
interventions due to their mental status. This allows physicians and nurses to be aware that close 
titration of lactulose needs to be done for the first few days of hospitalization. Perhaps, ordering 
a standing order of a lactulose enema would be beneficial for confused patients. Therefore, the 
nurse could go ahead and administer the enema if the patient has not been stooling enough. 
There was no significance for this population receiving a PRN lactulose dose or a lactulose 
enema on days 3, 4, and 5. Lastly, there was no significance in this population among narcotic 
use. This indicates that narcotic administration does not affect GCS score in this patient 
population.  
Limitations 
There were limitations identified in the design of the study. Data was collected through a 
retrospective chart review. Consequently, there was no way to verify the recorded results. 
Patients who are independent may have gotten up alone and had a bowel movement without 
reporting it to the nursing tech or registered nurse to enter into the chart. Nursing techs or 
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registered nurses might not remember to record every bowel movement their patient has had that 
day.  
Some patients had to be excluded from the study because lactulose was not started until later 
in their stay. When patients are first admitted, some health care providers do not start all the 
home medications right away and wait until they are stable to resume home medications. 
Therefore, some patients were not receiving lactulose until after five days of hospitalization, thus 
causing them to be excluded and lowering the patient population for the study.  
Calculating a MELD score involves getting specific lab values including INR, Cr, Na, and 
total bilirubin. All of these values need to be collected at the same time to calculate a MELD 
score. In some patients, the admit MELD score could not be calculated because some of the lab 
components were missing, specifically the INR value. This resulted in a smaller number of 
patients included for the MELD score analysis in this study.   
Recommendations for Future Studies 
Recommendations for future studies would include implementing a standardized lactulose 
order set for this patient population. This would allow for effective nurse/physician 
communication about the number of bowel movements the patients are having. The order set 
would guide nurses throughout the day on when to give scheduled and PRN lactulose. It would 
also tell nurses under what circumstances and when they should inform the physician if the 
patient has only had ≤ 1 bowel movement that day. After implementing this order set, the 
number of bowel movements could be analyzed to see if an increased number of patients are 
meeting the criteria of 2-4 daily bowel movements. Results of implementation of a standardized 
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lactulose order set could be compared to this study that does not have any standardization in 
place. Please refer to Table 7 for an example of a potential standardized lactulose order set.  
Another recommendation for future studies could be an assessment of nurse’s knowledge 
when titrating lactulose administration. Surveys could be given to nurses to ask whether or not 
they are paying attention to the number of bowel movements their patients are having, whether 
or not they communicate effectively with the nursing techs about the number of bowel 
movements their patients are having, and how they feel about communicating with the physician 
regarding the titration of lactulose and number of bowel movements their patients are having. 
These results could be beneficial to help find ways to improve patient outcomes in meeting the 
specific criteria for lactulose administration.  
Conclusion 
The goal of this study was to examine whether or not patients with liver disease receiving 
lactulose were meeting the goal of 2-4 bowel movements per day in the inpatient setting. 
Additional factors were analyzed including PRN lactulose and lactulose enema administration. 
The study population was broken down into those who had a MELD score ≥ 25 and those with 
daily average GCS of ≤ 14.5. These groups were further analyzed to see if they required 
additional lactulose interventions and narcotic administration was examined in the GCS group. 
The study showed that higher percentages of patients were not meeting the criteria of 2-4 daily 
bowel movements during the first five days of hospitalization. Patients with a MELD score of ≥ 
25 did not require additional lactulose interventions. Patients with a GCS of ≤ 14.5 required 
lactulose enemas on days 1 and 2 of hospitalization, indicating these patients should be closely 
monitored during the first few days of hospitalization. This knowledge lets physicians and nurses 
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realize that those who are confused may require additional lactulose interventions upon 
admission. Lastly, narcotic use was examined in those with a GCS ≤ 14.5 and it does not 
correlate with their mental status.  
This study can give providers a better understanding of lactulose titration and administration 
in the inpatient healthcare setting and show that not all patients may be meeting the specific 
protocol that the research proposes. Implementation of a standardized lactulose order set may 
allow for better lactulose titration and could be examined in a future study. Reducing the rates of 
HE in the hospital setting can reduce healthcare costs. It is important that nurses and doctors are 
monitoring the number of daily bowel movements their patients are having to prevent further 
complications from occurring.  
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List of Variables per Category  
Category Variables/Measures 
Demographic Measures 
Age age of participants in years 
Race American Indian/Alaskan Native, Asian, Native Hawaiian or Other 
Pacific Islander, Black or African American, White, Other, 
Unknown/not reported  
Gender Male, female 
Admitting diagnosis Diagnosis upon admission to the hospital 
Length of stay Number of days of hospitalization 
Process Measures 
 Daily PRN oral lactulose 
administration  
Yes or No daily for the first five days of hospitalization 
Daily lactulose enema 
administration 
Yes or No daily for the first five days of hospitalization 
Admit MELD score Calculated with admit lab work (day 1 of hospitalization) using 
Creatinine, International normalized ratio, Sodium, Bilirubin and 
dialysis frequency; score ranges from 6-40 
Average daily GCS score Average daily GCS for 0800 and 2000 for the first five days of 
hospitalization, 15 or ≤ 14.5 
Daily narcotic 
administration 
Yes or No daily for the first five days of hospitalization 
Outcome Measures  
Daily number of bowel 
movements 
Number of daily bowel movements for the first five days of 
hospitalization 
Notes: Length of stay (LOS), Model for End Stage Liver Disease (MELD), Creatinine (Cr), International 
normalized ratio (INR), Sodium (Na), Bilirubin (bili), Glascow Coma Scale (GCS) 
 
Table 1: List of variables per category.  
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Narcotics Administered in this Study  
Generic Name Brand Name 
Propofol Diprovan 
Oxycodone Oxycontin 
Morphine Duramorph 
Hydromorphone Dilaudid  
Hydrocodone/Acetaminop
hen 
Norco 
Tramadol Ultram 
Table 2: Narcotics Administered in this Study  
 Mean (SD) or n (%) 
Age 57.6 (10.7) 
Sex 
   Male  
  Female  
 
36 (51.4%) 
34 (48.6%) 
 
Ethnicity 
   Black or African American 
   White 
    
 
3 (4.3%) 
67 (95.7%) 
Admitting Diagnosis  
    Liver Disease Etiology  
    Non-liver Disease Etiology  
 
 
26 (37.1%) 
44 (62.9%) 
Length of Stay  
        
Median (Range) 
11.5 (6-20) 
Table 3. Demographics of patients in the study. (N=70) 
 Day 1  Day 2 Day 3 Day 4 Day 5  
 Y N Y N Y N Y N Y N 
Meet the 
goal of 2-
4 BM’s 
per day? 
 
 
 
22.64% 
 
 
 
77.36% 
 
 
 
43.64% 
 
 
 
56.36
% 
 
 
 
44.44
% 
 
 
 
55.56
% 
 
 
 
 
41.54% 
 
 
 
 
 
58.46
% 
 
 
 
34.38% 
 
 
 
65.63
% 
Table 4.  Percentage of patients who met the goal of 2-4 bowel movements (BMs) each day for 
the first five days of hospitalization.  
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 Day 1  Day 2 Day 3 Day 4 Day 5  
 Y N Y N Y N Y N Y N	
Meet the 
goal of 2-
4 BM’s 
per day? 
 
 
 
22.22% 
 
 
 
25.81
% 
 
 
 
52.63
% 
 
 
 
40.63
% 
 
 
 
36.36
% 
 
 
 
51.53
% 
 
 
 
 
43.48
% 
 
 
 
 
 
34.21
% 
 
 
 
43.48
% 
	
	
	
32.43%	
P 1.000 0.4048 0.2638 0.4692 0.3880 
 Y N Y N Y N Y N Y N	
Received 
PRN dose 
of 
lactulose? 
 
4.76% 
 
0.00 
 
14.29
% 
 
0.00 
 
9.09% 
 
5.41% 
 
8.70
% 
 
5.26% 
 
8.70
% 
	
2.63%	
P 0.3889 0.0536 0.6244 0.6282 0.5507 
 Y N Y N Y N Y N Y N	
Received 
lactulose 
enema?  
 
4.76% 
 
15.15
% 
 
4.76% 
 
12.12
% 
 
0.000 
 
5.41% 
 
13.04
% 
 
5.26% 
 
4.35
% 
	
5.26%	
P 0.3863 0.6377 0.5243 0.3559 1.000 
Table 5: Chi square: Percentage of patients with a MELD score of ³ 25 who met the goal of 2-4 
BM’s per day, received a PRN dose of lactulose, received a lactulose enema, and received a 
narcotics each day for the first five days of hospitalization.  
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 Day 1  Day 2 Day 3 Day 4 Day 5  
 Y N Y N Y N Y N Y N 
Meet the 
goal of 2-
4 BM’s 
per day? 
 
 
 
66.67% 
 
 
 
29.27
% 
 
 
 
33.33
% 
 
 
 
41.94
% 
 
 
 
 
42.86
% 
 
 
 
31.43
% 
 
 
 
 
37.04
% 
 
 
 
 
 
39.47
% 
 
 
 
45.45
% 
 
 
 
40.48
% 
P 0.0390 0.5149 0.3492 0.8423 0.7017 
 Y N Y N Y N Y N Y N 
Received 
PRN 
dose of 
lactulose
? 
 
0.000 
 
2.86% 
 
4.55
% 
 
5.71
% 
 
13.04
% 
 
2.50
% 
 
16.00
% 
 
2.50
% 
 
10.71
% 
 
2.70% 
P 1.000 1.000 0.1338 0.0677 0.3068 
 Y N Y N Y N Y N Y N 
Received 
lactulose 
enema?  
 
 
27.27
% 
 
 
0.000 
 
 
22.73
% 
 
 
0.000 
 
 
8.70
% 
 
 
0.000 
 
 
8.00 
 
 
7.5% 
 
 
7.14
% 
 
 
2.70% 
P 0.0021 0.0063 0.1295 1.000 0.5731 
 Y N Y N Y N Y N Y N 
Received 
Narcotics
?  
 
 
31.82
% 
 
 
38.89
% 
 
 
45.45
% 
 
 
42.86
% 
 
 
43.48
% 
 
 
45.00
% 
 
 
44.00
% 
 
 
45.00
% 
 
 
46.43
% 
 
 
40.54
% 
P 0.5867 0.8474 0.9068 0.9371 0.6350 
Table 6: Chi square: Percentage of patients with a GCS of £ 14.5 who met the goal of 2-4 BM’s 
per day, received a PRN dose of lactulose, received a lactulose enema, and received a narcotic 
each day for the first five days of hospitalization.  
Time Intervention 
0800 Give scheduled 30 mL dose of Lactulose 
1200 If patient has not had a bowel movement by 
this time, give PRN 30 mL dose of lactulose 
1400 Give scheduled 30 mL dose of Lactulose 
1600 If patient has ≤ 1 bowel movement by this 
time, notify physician for next intervention.  
2000 Give scheduled 30 mL dose of Lactulose 
 
Table 7: Standardized Lactulose Order Set example to implement in future studies.  
